華為嘗試向中東及東南亞出口少量AI晶片
華為正嘗試向中東及東南亞市場出口少量人工智能(AI)晶片,希望打入由美國晶片巨頭英偉達(NVDA.US)主導的市場。據知情人士透露,華為近期已聯絡阿聯酋、沙地阿拉伯及泰國的潛在客戶,推銷其舊款Ascend 910B處理器。
消息人士指,華為目前提供的910B晶片數量為「低千級」,但每次交易的實際數量則未有明確。為吸引客戶,華為亦提供對CloudMatrix 384系統的遠程存取權限。該系統設於中國,以更高階的Ascend 910C晶片建構。然而,據悉由於供應有限,華為暫未有計劃向海外出口910C,並優先保留予無法獲得美國頂尖晶片的中國本土企業。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.